BioLineRx Valuation
| BLRX Stock | USD 3.22 0.06 1.90% |
At this time, the firm appears to be undervalued. BioLineRx shows a prevailing Real Value of $3.83 per share. The current price of the firm is $3.22. Our model approximates the value of BioLineRx from analyzing the firm fundamentals such as Return On Equity of -1.84, profit margin of (0.91) %, and Current Valuation of 12.09 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting BioLineRx's valuation include:
Price Book 1.3221 | Enterprise Value | Enterprise Value Ebitda (0.67) | Price Sales 0.5113 | Enterprise Value Revenue 0.5499 |
Undervalued
Today
Please note that BioLineRx's price fluctuation is very risky at this time. Calculation of the real value of BioLineRx is based on 3 months time horizon. Increasing BioLineRx's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BioLineRx is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioLineRx Stock. However, BioLineRx's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.22 | Real 3.83 | Target 4.57 | Hype 2.91 |
The intrinsic value of BioLineRx's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence BioLineRx's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of BioLineRx helps investors to forecast how BioLineRx stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioLineRx more accurately as focusing exclusively on BioLineRx's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use BioLineRx's intrinsic value based on its ongoing forecasts of BioLineRx's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against BioLineRx's closest peers.
BioLineRx Cash |
|
BioLineRx Valuation Trend
Analysing the historical paterns of BioLineRx's enterprise value and its market capitalization is a good way to estimate and gauge the value of BioLineRx over time and is usually enough for investors to make rational market timing decisions.
BioLineRx Total Value Analysis
BioLineRx is currently projected to have valuation of 12.09 M with market capitalization of 11.24 M, debt of 11.59 M, and cash on hands of 43.15 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the BioLineRx fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
12.09 M | 11.24 M | 11.59 M | 43.15 M |
BioLineRx Investor Information
The company has price-to-book (P/B) ratio of 1.32. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioLineRx has Price/Earnings To Growth (PEG) ratio of 0.2. The entity recorded a loss per share of 12.0. The firm last dividend was issued on the 15th of July 2019. BioLineRx had 1:40 split on the 30th of January 2025. Based on the key measurements obtained from BioLineRx's financial statements, BioLineRx is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.BioLineRx Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BioLineRx has an asset utilization ratio of 7.51 percent. This suggests that the Company is making $0.0751 for each dollar of assets. An increasing asset utilization means that BioLineRx is more efficient with each dollar of assets it utilizes for everyday operations.BioLineRx Ownership Allocation
The market capitalization of BioLineRx is $11.24 Million. BioLineRx shows 4.67 percent of its outstanding shares held by insiders and 1.4 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.BioLineRx Profitability Analysis
The company reported the previous year's revenue of 4.8 M. Net Loss for the year was (60.61 M) with profit before overhead, payroll, taxes, and interest of 15.12 M.About BioLineRx Valuation
Our relative valuation model uses a comparative analysis of BioLineRx. We calculate exposure to BioLineRx's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioLineRx's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 997.2 K | 947.3 K | |
| Pretax Profit Margin | (14.52) | (13.80) | |
| Operating Profit Margin | (11.91) | (11.31) | |
| Net Loss | (14.52) | (13.80) | |
| Gross Profit Margin | 0.27 | 0.25 |
BioLineRx Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 963.4 M |
BioLineRx Current Valuation Indicators
Valuation refers to the process of determining the present value of BioLineRx and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value BioLineRx we look at many different elements of the entity such as BioLineRx's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as BioLineRx, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use BioLineRx's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes BioLineRx's worth.Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.